Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 1/20 | 0.57 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.45 |
| ▸ | EGFR | P00533 | 1/20 | 0.43 |
| ▸ | CA1 | P00915 | 3/20 | 0.42 |
| ▸ | CA2 | P00918 | 3/20 | 0.42 |
| ▸ | CA12 | O43570 | 2/20 | 0.42 |
| ▸ | CA9 | Q16790 | 2/20 | 0.42 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | CA7 | P43166 | 1/20 | 0.42 |
| ▸ | MYC | P01106 | 1/20 | 0.41 |
| ▸ | WDR5 | P61964 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 4/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13229757 | 0.87 | PTGS1 (0.43) | PTGS1POLBRXFP1CA1CA2 | |
| SCHEMBL9169122 | 0.86 | CA12 (0.46) | PTGS1POLBRXFP1CA1CA2 | |
| SCHEMBL7823119 | 0.83 | PLAU (0.44) | PTGS1CA1CA2CA12CA9 | |
| SCHEMBL13229756 | 0.82 | PTGS1 (0.40) | PTGS1POLBRXFP1EGFRCA1 | |
| SCHEMBL20262093 | 0.81 | PTGS1 (0.62) | PTGS1POLBRXFP1EGFRCA1 | |
| SCHEMBL3195110 | 0.81 | HDAC3 (0.45) | PTGS1TP53ALDH1A1TSHRKDM4E | |
| SCHEMBL15997796 | 0.80 | PGR (0.39) | PTGS1POLBRXFP1PGR | |
| SCHEMBL3722137 | 0.75 | EGFR (0.51) | PTGS1EGFRCA1CA2CA12 | |
| SCHEMBL17837166 | 0.74 | POLB (0.49) | POLBRXFP1TDP1MAPTKMT2A | |
| Biphenyl Dimethyl Dicarboxylate SCHEMBL2890577 | 0.73 | CA1 (0.67) | EGFRCA1CA2CA12CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2772484-B1 | BICYCLIC HETEROCYCLIC COMPOUND | ASTELLAS PHARMA INC (JP) | 2017-06-28 | — | — | EP | disclosed |
| US-9266840-B2 | Bicyclic heterocyclic compound | ASTELLAS PHARMA INC. (JP) | 2016-02-23 | — | — | US | disclosed |
| US-9266840-B2 | Bicyclic heterocyclic compound | ASTELLAS PHARMA INC. (JP) | 2016-02-23 | — | — | US | disclosed |
| US-20140249151-A1 | BICYCLIC HETEROCYCLIC COMPOUND | ASTELLAS PHARMA INC. (JP) | 2014-09-04 | — | — | US | disclosed |
| US-20140249151-A1 | BICYCLIC HETEROCYCLIC COMPOUND | ASTELLAS PHARMA INC. (JP) | 2014-09-04 | — | — | US | disclosed |
| WO-2013058258-A1 | BICYCLIC HETEROCYCLIC COMPOUND | アステラス製薬株式会社 (JP) | 2013-04-25 | — | — | WO | disclosed |
| US-20100029608-A1 | Histamine H3 Receptor Agents, Preparation and Therapeutic Uses | FINLEY DON RICHARD | 2010-02-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140249151-A1 | BICYCLIC HETEROCYCLIC COMPOUND | HSD11B1, HSD17B11, HSD17B1 | PTGS1 94/4885POLB 1682/4885RXFP1 4184/4885 |
| US-20100029608-A1 | Histamine H3 Receptor Agents, Preparation and Therapeutic Uses | HRH3, HRH4, HCRTR1 | PTGS1 2379/4885POLB 4356/4885RXFP1 208/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.